|
1.
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar
|
|
2.
|
Bott SR, Birtle AJ, Taylor CJ and Kirby
RS: Prostate cancer management: 2. An update on locally advanced
and metastatic disease. Postgrad Med J. 79:643–645. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Timsit MO, Lebret T and Méjean A:
Chemotherapy of hormonorefractory and hormonoresistant metastatic
prostate cancer. Prog Urol. 18(Suppl 7): S365–S375. 2008.(In
French).
|
|
4.
|
Carthew RW and Sontheimer EJ: Origins and
mechanisms of miRNAs and siRNAs. Cell. 136:642–655. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Bartel DP: MicroRNAs: genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Filipowicz W, Bhattacharyya SN and
Sonenberg N: Mechanisms of post-transcriptional regulation by
microRNAs: are the answers in sight? Nat Rev Genet. 9:102–114.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Friedman RC, Farh KK, Burge CB and Bartel
DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome
Res. 19:92–105. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Hobert O: Gene regulation by transcription
factors and microRNAs. Science. 319:1785–1786. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Iorio MV and Croce CM: MicroRNAs in
cancer: small molecules with a huge impact. J Clin Oncol.
27:5848–5856. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Kwak PB, Iwasaki S and Tomari Y: The
microRNA pathway and cancer. Cancer Sci. 101:2309–2315. 2010.
View Article : Google Scholar
|
|
11.
|
Esquela-Kerscher A and Slack FJ: Oncomirs
- microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006.
View Article : Google Scholar
|
|
12.
|
Fuse M, Kojima S, Enokida H, et al: Tumor
suppressive microRNAs (miR-222 and miR-31) regulate molecular
pathways based on microRNA expression signature in prostate cancer.
J Hum Genet. 57:691–699. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Kojima S, Enokida H, Yoshino H, et al: The
tumor-suppressive microRNA-143/145 cluster inhibits cell migration
and invasion by targeting GOLM1 in prostate cancer. J Hum Genet.
59:78–87. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Kojima S, Chiyomaru T, Kawakami K, et al:
Tumour suppressors miR-1 and miR-133a target the oncogenic function
of purine nucleoside phosphorylase (PNP) in prostate cancer. Br J
Cancer. 106:405–413. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Chiyomaru T, Enokida H, Tatarano S, et al:
miR-145 and miR-133a function as tumour suppressors and directly
regulate FSCN1 expression in bladder cancer. Br J Cancer.
102:883–891. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Fuse M, Nohata N, Kojima S, et al:
Restoration of miR-145 expression suppresses cell
proliferation, migration and invasion in prostate cancer by
targeting FSCN1. Int J Oncol. 38:1093–1101. 2011.
|
|
17.
|
Kinoshita T, Nohata N, Hanazawa T, et al:
Tumour-suppressive microRNA-29s inhibit cancer cell migration and
invasion by targeting laminin-integrin signalling in head and neck
squamous cell carcinoma. Br J Cancer. 109:2636–2645. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Yamamoto N, Kinoshita T, Nohata N, et al:
Tumor-suppressive microRNA-29a inhibits cancer cell
migration and invasion via targeting HSP47 in cervical
squamous cell carcinoma. Int J Oncol. 43:1855–1863. 2013.
|
|
19.
|
Wang Y, Zhang X, Li H, Yu J and Ren X: The
role of miRNA-29 family in cancer. Eur J Cell Biol. 92:123–128.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Maurer B, Stanczyk J, Jüngel A, et al:
MicroRNA-29, a key regulator of collagen expression in systemic
sclerosis. Arthritis Rheum. 62:1733–1743. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Roderburg C, Urban GW, Bettermann K, et
al: Micro-RNA profiling reveals a role for miR-29 in human and
murine liver fibrosis. Hepatology. 53:209–218. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Yang T, Liang Y, Lin Q, et al: miR-29
mediates TGFbeta1-induced extracellular matrix synthesis through
activation of PI3K-AKT pathway in human lung fibroblasts. J Cell
Biochem. 114:1336–1342. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Nelson CM and Bissell MJ: Modeling dynamic
reciprocity: engineering three-dimensional culture models of breast
architecture, function, and neoplastic transformation. Semin Cancer
Biol. 15:342–352. 2005. View Article : Google Scholar
|
|
24.
|
Gassmann P, Enns A and Haier J: Role of
tumor cell adhesion and migration in organ-specific metastasis
formation. Onkologie. 27:577–582. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
White DE, Rayment JH and Muller WJ:
Addressing the role of cell adhesion in tumor cell dormancy. Cell
Cycle. 5:1756–1759. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Heldin CH, Vanlandewijck M and Moustakas
A: Regulation of EMT by TGFbeta in cancer. FEBS Lett.
586:1959–1970. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Skobe M and Fusenig NE: Tumorigenic
conversion of immortal human keratinocytes through stromal cell
activation. Proc Natl Acad Sci USA. 95:1050–1055. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Olumi AF, Grossfeld GD, Hayward SW,
Carroll PR, Tlsty TD and Cunha GR: Carcinoma-associated fibroblasts
direct tumor progression of initiated human prostatic epithelium.
Cancer Res. 59:5002–5011. 1999.PubMed/NCBI
|
|
29.
|
Brown LF, Guidi AJ, Schnitt SJ, et al:
Vascular stroma formation in carcinoma in situ, invasive carcinoma,
and metastatic carcinoma of the breast. Clin Cancer Res.
5:1041–1056. 1999.PubMed/NCBI
|
|
30.
|
Jensen BV, Johansen JS, Skovsgaard T,
Brandt J and Teisner B: Extracellular matrix building marked by the
N-terminal propeptide of procollagen type I reflect aggressiveness
of recurrent breast cancer. Int J Cancer. 98:582–589. 2002.
View Article : Google Scholar
|
|
31.
|
Aumailley M: The laminin family. Cell Adh
Migr. 7:48–55. 2013. View Article : Google Scholar
|
|
32.
|
Tzu J and Marinkovich MP: Bridging
structure with function: structural, regulatory, and developmental
role of laminins. Int J Biochem Cell Biol. 40:199–214. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Yamaguchi M, Ebihara N, Shima N, et al:
Adhesion, migration, and proliferation of cultured human corneal
endothelial cells by laminin-5. Invest Ophthalmol Vis Sci.
52:679–684. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Kinoshita T, Hanazawa T, Nohata N, et al:
Tumor suppressive microRNA-218 inhibits cancer cell migration and
invasion through targeting laminin-332 in head and neck squamous
cell carcinoma. Oncotarget. 3:1386–1400. 2012.
|
|
35.
|
Nde PN, Simmons KJ, Kleshchenko YY, Pratap
S, Lima MF and Villalta F: Silencing of the laminin gamma-1 gene
blocks Trypanosoma cruzi infection. Infect Immun.
74:1643–1648. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Toti P, Villanova M, De Felice C, Megha T,
Bartolommei S and Tosi P: Expression of laminin 1 and 2 in brain
tumor vessels. An immunohistochemical study. J Submicrosc Cytol
Pathol. 30:227–230. 1998.PubMed/NCBI
|
|
37.
|
Ke HL, Ke RH, Li B, Wang XH, Wang YN and
Wang XQ: Association between laminin γ1 expression and meningioma
grade, recurrence, and progression-free survival. Acta Neurochir.
155:165–171. 2013.
|
|
38.
|
Kuratomi Y, Nomizu M, Tanaka K, et al:
Laminin gamma 1 chain peptide, C-16 (KAFDITYVRLKF), promotes
migration, MMP-9 secretion, and pulmonary metastasis of B16-F10
mouse melanoma cells. Br J Cancer. 86:1169–1173. 2002. View Article : Google Scholar : PubMed/NCBI
|
